Skip to main content
. Author manuscript; available in PMC: 2014 Mar 9.
Published in final edited form as: Oncogene. 2012 Oct 8;32(36):4252–4263. doi: 10.1038/onc.2012.438

Figure 6. Strong tumorigenicity of CD49f−CD133+ cells correlates with inhibited osteogenic capacity.

Figure 6

(A) Both CD133+ and CD133− subpopulations of UT2 (left panel) or KHOS/PN cells (right panel) displayed osteogenic and adipogenic differentiation, as judged by ARS and ORO staining. (B) CD49f−CD133+ cells but not CD49f−CD133− cells formed tumors in NOD/SCID mice (left panel); HE staining of CD49f−CD133+ xenograft cells showed the histological features of U2OS cells with osteoid (extra-cellular matrix) formation, as reflected by spindle cells with a vesicular nucleus often containing prominent nucleoli, frequent mitotic activities, and focal areas of osteoid formation (middle panel); engrafted CD49f−CD133+ cells differentiated to CD49f+ cells in mice (right panel). (C) While both CD49f−CD133+ and CD49f−CD133− cells showed a similar capacity for fat differentiation (sections 3 and 4), CD49f−CD133+ cells showed a reduced potential for bone differentiation, compared to CD49f−CD133− cells and MSC (sections 1 vs. 2 and 6). (D) Microarray analysis revealed a decreased expression of osteogenic marker genes in UT2 cells. (E & F) qRT-PCR analysis of osteogenic (panel E) and adipogenic marker gene expressions (panel F) in CD49f− and CD49f+ subpopulations.

HHS Vulnerability Disclosure